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Background: Glutamate dehydrogenase (GDH) is a key enzyme that catalyzes the final reaction of the glutamine
metabolic pathway, and has been reported implicated in tumor growth and metastasis. However, it’s clinical
significance and role in colorectal cancer (CRC) pathogenesis is largely unknown.
Methods: The expression of GDH was determined by qPCR, western blot and immunohistochemistry in CRC cells
and samples. The correlation of GDH expression with clinicopathologic features and prognosis was analyzed. The
functional role of GDH in CRC cell proliferation, motility and metastasis was evaluated.
Results: We found that GDH was up-regulated both in colorectal cancer and metastatic lesions (n = 104). Patients
with high GDH expression had poorer overall survival (HR 2.32; 95% CI 1.26-4.26; P = 0.007) and poorer disease-free
survival rates (HR 2.48; 95% CI 1.25-4.92; P = 0.009) than those with low GDH expression. Furthermore, we showed
that GDH expression was an independent prognostic factor for CRC. In addition, over-expression of GDH promoted
cell proliferation, migration and invasion in vitro, whereas loss function of GDH did the opposite. Finally, we
demonstrated that the promotion of CRC progression by GDH correlated with activation of STAT3 mediated
epithelial-mesenchymal transition (EMT) induction.
Conclusions: These results indicate that GDH plays a critical role in CRC progression, and may provide a novel
metabolism therapeutic target for CRC treatment.
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Colorectal cancer (CRC) is one of the leading causes of can-
cer mortality in most courtiers, and globally affects over a
million people each year in the developed countries [1].
Distant metastasis through lymphatic or hematogenous dis-
semination contributes to a poor prognosis for CRC, and
the liver is the most frequent site of distant metastasis of
CRC [2].* Correspondence: chaomingtt001@163.com; zengbing2007@163.com
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stated.Currently, liver resection remains a standard proced-
ure and the only potentially curative therapy for colorec-
tal liver metastases (CLM). Unfortunately, the initial
resection rates are reported to be less than 25% [3], with
a high recurrence rate of 70–80% after curative resection
[4]. Chemotherapy alone or in addition to local minim-
ally invasive treatment, such as radiofrequency ablation,
transarterial chemotherapy, or percutaneous ethanol in-
jection, is the most treatment options in those who are
not suitable for resection [5]. However, the underlying
mechanism of this aggressive biology of CRC is largely
unknown.
Aberrant energy metabolism is a critical hallmark for
many types of human tumors [6]. Increasingly evidences
have shown that glutamine metabolism plays key roless is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
zero/1.0/) applies to the data made available in this article, unless otherwise
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comes [7-9]. Glutamine is first catabolyzed to glutamate
and than to generate a-ketoglutarate, a tricarboxylic acid
(TCA) cycle intermediate. Glutaminolysis supports the
viability of cancer cells by supporting ATP production
and by the biosynthesis of proteins, lipids, and nucleo-
tides, and suppress oxidative stress through glutathione
synthesis [10]. More importantly, oncogenes and tumor
suppressors, such as SIRT4, mTORC1, K-RAS and p53,
have been implicated in the regulation of glutamine
metabolism [11-14]. Accordingly, it positively regulates
the mTORC1 pathway by facilitating the uptake of leu-
cine [15], and regulates STAT3 pathway by promoting
tyrosine Y705 phosphorylation [9].
Glutamate dehydrogenase (GDH) is an enzyme that
plays a pivotal role in glutamine metabolism by convert-
ing glutamate to a-ketoglutarate, especially when glucose
is insufficient or under hypoxia. Recently, Csibi and
coworkers [16] reported that mTORC1 promoted gluta-
minolysis by activating GDH to facilitate cell proliferation,
transformation, and tumor development by repressing
SIRT4. Lorin and colleagues [15] found that GDH contrib-
uted to autophagy by activating mTORC1 and by limiting
the formation of reactive oxygen species in transformed
cells. Yang [17] demonstrated that GDH activity is re-
quired for glioblastoma cell to survive impairments of gly-
colysis brought about by glucose deprivation. Moreover,
studies found that treatment with epigallocatechin gallate
(EGCG), an allosteric inhibitor of GDH, has considerable
effect on tumor growth [18,19]. However, the clinical sig-
nificance and role of GDH expression in colorectal cancer
has not yet been investigated.
In the present study, we examined the expression of
GDH in CRC and further analyzed the clinical significance
of GDH in a cohort of CRC patients. In addition, we
explored the potential role of GDH in CRC cell prolifera-
tion and motility, which could help to better understand
the pathogenesis of CRC and may further provide a novel
therapeutic target for the treatment of CRC patients.
Materials
Cell culture, reagents and Lentiviral transduction
The human colon cancer cell lines HCT116, DLD-1,
SW480, RKO and LoVo were grown in RPMI-1640
medium supplemented with 10% fetal bovine serum
(FBS). The human colon epithelial cell line NCM460
was cultured in MEM medium supplemented with 10%
FBS. All cell lines were maintained at 37°C in a humidi-
fied atmosphere with 5% CO2.
AG490 and DMSO were obtained from Sigma. The
GDH short hairpin RNA (shRNA) was synthesized and
cloned into a pLKO.1-TRC vector (Addgene). These
vectors were co-transfected into 293 T cells along with
the retroviral packaging plasmid. After transfection, thesupernatants were harvested and used to infect CRC
cells, and the stably transfected cells were selected with
puromycin according the manufacturer’s protocol.
Tumor specimens
Twenty freshly frozen CRC samples and corresponding
non tumor tissues were obtained from Sun Yat-sen Me-
morial Hospital of Sun Yat-sen University. In addition,
we collected 104 paraffin embedded CRC specimens
from our hospital between January 2002 and February
2005. Tumor staging for the specimens was carried out
according to the American Joint Committee on Cancer sta-
ging criteria. The median follow-up time was 62.5 months
(range from 6.7 to 99). The patients’ overall survival (OS)
and disease-free survival (DFS) durations were defined
as the interval from initial surgery to death and from
initial surgery to clinically proven recurrence or metas-
tasis respectively. The study was approved by the Insti-
tute Research Ethics Committee at the Sun Yat-sen
University, and written informed consent was obtained
from each patient.
Immunohistochemical analysis
Sections of paraffin-embedded CRC specimens were pre-
pared and standard immunohistochemical procedures
were carried out as previously described [20]. Briefly,
samples were deparaffinized and rehydrated, and the
endogenous peroxidase activity was quenched. Antigen
retrieval was performed, and the sections were blocked
with bovine serum albumin and then incubated with anti-
GDH antibody (Abcam; 1:200). Sections were washed and
then incubated with a biotinylated secondary antibody and
visualized with 3,3-diaminobenzidine.The staining results
were scored by two pathologists blinded to the clinical
data. Staining index was calculated as the product of the
staining intensity (0, no staining; 1, weak staining; 2,
moderate staining; 3, strong staining) and the propor-
tion of positive cells (0, no positive tumor cells; 1, <10%;
2, 10-35%; 3, 35-70%; 4, >70%). The immunoreactivity
score (IRS) was resulted from the multiplication of both
parameters. Using this method of assessment, we evalu-
ated GDH expression by determining the IRS, with scores
of 0, 1, 2, 3, 4, 6, 8, 9 or 12. The samples were divided into
2 groups as follows: low (IRS = 0–4), and high (IRS ≥6).
RNA extraction and quantitative real-time PCR
Total RNA was extracted using TRIzol reagent. The
reverse-transcription PCR (RT-PCR) was performed using
transcriptase, and the quantitative real-time PCR (qRT-
PCR) was performed in a LightCycler480 System using a
SYBR Premix ExTaq kit according to the manufacturer’s
instructions. Primers for qRT-PCR are as follows. GDH:
Forward, 5′-GGG ATT CTA ACT ACC ACT TGC TCA-
3′, Reverse 5′-AAC TCT GCC GTG GGT ACA AT-3′.
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CAG C-3′, Reverse, 5′-CCC AAT ACG ACC AAA TCC
GTT-3′. The relative expression levels were calculated
by the 2-ΔΔCT method. Each assay was carried out in
triplicate.
Western blot analysis
Cell cytosolic protein fractions were prepared using
RIPA buffer. According to standard Western blot proce-
dures, briefly, proteins were separated by SDS-PAGE
and then transferred to polyvinylidene fluoride (PVDF)
membranes. After blocking in 5% nonfat milk, the
membranes were incubated with the following primary
antibodies: GDH antibody (Abcam), STAT3, pSTAT3
(Tyr705), E-Cadherin, Vimentin, ZEB1 and GAPDH
antibody (Cell Signaling Technology) according to the
manufacturer’s instructions.
Cell proliferation
Cell proliferation was analysed with the MTT assay.
Cells were seeded in 96-well plates at a density of 1,000
cells per well. At 1, 2, 3 and 4 days, the cells were
stained with 20 μl of MTT (0.5 mg/ml) for 4 h, and after
which the medium was removed, and 100 μl of DMSO
was added. The absorbance was measured at 490 nm.
The anchorage-independent sphere formation assay was
performed by culturing the cells in suspension in serum-
free DMEM-F12 supplemented with B27 (Invitrogen),
EGF (BD Biosciences, CA, USA), 0.4% bovine serum
albumin (Sigma, MO, USA), and insulin (Sigma).
Cell migration and invasion assays
Cell motility was assessed by wound healing assay as
previously described [21]. Results were expressed as a
migration index: the distance migrated by targeted
relative to the distance migrated by control cells. Cell
invasion assays were performed using 24-well trans-
wells (8-μm pore size, BD Sciences) coated with matri-
gel (1 mg/ml, BD Sciences), as previously described
[21]. The inserts were stained with 0.2% crystal violet,
imaged, and counted under an inverted microscope in
six randomly selected fields. All experiments were car-
ried out in triplicate and repeated at least three times.
Statistical analysis
Data are presented as the mean ± SD, and differences be-
tween groups were analyzed using Student’s t-test or
chi-squared test or fisher exact test. The Kaplan-Meier
method and log-rank test were used to estimate survival
rates. Cox proportional hazards model was used to
calculate univariate and multivariate hazard ratios for
the study variables. Statistical analyses were performed
with SPSS 16.0 software (Chicago, IL), and P values
of < 0.05 were considered statistically significant.Results
Expression of GDH in CRC cells and tissues
Quantitative RT-PCR and western blot were used to de-
termine the levels of GDH mRNA and protein in CRC
cell lines. As shown in Figure 1A and B, GDH was over-
expressed in CRC cell lines when compared to human
colon epithelial cell line NCM460. LoVo (P = 0.0003),
HCT116 (P = 0.0036), HCT116 (P = 0.0019). Next, we
analyzed GDH mRNA expression in 20 freshly frozen
CRC tissues and corresponding non tumor tissues. We
found that GDH expression levels were considerably
over-expressed in CRC when compared to correspond-
ing non tumor tissues (Figure 1C). Moreover, GDH pro-
tein expression levels were also up-regulated in tumor
tissues (Figure 1D).GDH over-expression is associated with CRC metastasis
To determine the effect of GDH expression on CRC
progression, we next analyzed the expression of GDH
protein in a set of 104 paraffin embedded CRC tissue
using immunohistochemistry. Representative staining of
GDH in CRC tissue is shown in Figure 2. We observed
that GDH was highly expressed in 56 of the 104 (53.8 %)
patients, and GDH-positive staining was mainly in the
cytoplasm of the cancer cells. Interestingly, immuno-
staining results showed that metastatic lymph nodes and
liver metastases lesions had higher levels of GDH
expression (Figure 2E and F).
Furthermore, patients with high GDH expression exhib-
ited a significant association with tumor size (P = 0.046),
tumor stage (P = 0.001), lymph node metastasis (P = 0.001)
and liver metastasis (P = 0.021). While there were no sig-
nificant associations between GDH expression and age,
sex, location, grade of differentiation, T stage, CEA, venous
invasion, or nervous invasion (Table 1).GDH over-expression is association with poor prognosis
in CRC patients
To assess the clinical significance of GDH over-expression
in CRC, Kaplan-Meier analysis and the log-rank test were
used to analyze the relationship between GDH expression
and patient survival. We found that the 5-year overall sur-
vival (OS) was significantly lower in patients with high
GDH expression than in those with low GDH expression
(38.1% vs. 65.1%; HR 2.32; 95% CI 1.26-4.26; P = 0.007)
(Figure 3A). Moreover, patients with high GDH expression
were significantly associated with poorer disease-free sur-
vival (DFS) rates than those with low GDH expression
(HR 2.48; 95% CI 1.25-4.92; P = 0.009) (Figure 3B). In
addition, multivariate analyses indicated that GDH ex-
pression, lymph node metastasis, and liver metastasis
were independent prognostic indicators for both OS
and DFS in CRC patients (Table 2).
Figure 1 Expression levels of GDH in CRC cell lines and clinical samples. (A-B) Expression levels of GDH mRNA and protein in NCM460 and CRC
cell lines. (C-D) Expression levels of GDH mRNA and protein in CRC tissues and corresponding non tumor tissues. GAPDH was used as the
endogenous control. Data are presented as the mean ± SD, and P values were calculated with Student’s t-test.
Figure 2 Expression levels of GDH in CRC tissues, metastatic lymph nodes and liver metastases lesions. Representative images of CRC tissues with
GDH Negative staining (A), Weak staining: light yellow (B), moderate staining: yellow brown (C), strong staining: brown (D). Representative
images of GDH immunostaining in metastatic lymph nodes (E) and liver metastases lesions (F). (Envision × 40, × 400).
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Table 1 Clinicopathological factors and GDH expression in 104 colorectal cancers
Factor GDH high expression GDH low expression P-value
n = 56, n (%) n = 48, n (%)
Age
<60 27 48.2 26 54.2 0.545
≥60 29 51.8 22 45.8
Gender
Male 34 60.7 27 56.2 0.645
Female 22 39.3 21 43.8
Location
Colon 33 58.9 32 66.7 0.416
Rectum 23 41.1 16 33.3
Tumor size
<3cm 24 42.9 30 62.5 0.046*
≥3cm 32 57.1 18 37.5
CEA
Normal 26 46.4 25 52.1 0.656
Elevated 30 53.6 23 47.9
Grade of differentiation
Well 11 19.6 14 29.2 0.296
Moderate 35 62.5 27 56.3
Poor 10 17.9 7 14.5
Depth of invasion
T1 and T2 31 55.4 26 54.2 0.903
T3 and T4 25 44.6 22 45.8
Tumor stage
I and II 14 25 28 58.3 0.001*
III and IV 42 75 20 41.7
Lymph node metastasis
Negative 20 35.7 33 68.8 0.001*
Positive 36 64.3 15 31.2
Liver metastasis
Negative 40 71.4 43 89.6 0.021*
Positive 16 28.6 5 10.4
Venous invasion
Negative 50 89.3 45 93.8 0.501
Positive 6 10.7 3 6.2
Nervous invasion
Negative 36 64.3 38 79.2 0.095
Positive 20 35.7 10 20.8
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motility in vitro
To confirm the functional role of GDH in CRC cells,
we first transfected shGDH or scrambled plasmid
into CRC cells (Additional file 1: Figure S1), and
found that GDH depletion significantly suppressedcell proliferation and inhibited anchorage-independent
growth compared to the controls (Figure 4A and B).
Next, the wound healing assay showed that down-
regulation of GDH led to a marked decrease in cell
motility than that of control cells (Figure 4C). Simi-
larly, the transwell invasion assay demonstrated that
Figure 3 Kaplan-Meier curves for OS and DFS. Patients with high GDH expression had poorer overall survival (A) and poorer disease-free survival
(B) rates than patients with low GDH expression.
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cell invasion (Figure 4D).
GDH promotes CRC cell motility via STAT3 mediated EMT
Induction
Epithelial-mesenchymal transition (EMT) contributes to
tumor invasion and metastasis in many cancers includ-
ing CRC [22]. Previous studies found that glutamine
metabolism could promote tumor growth and invasion
through STAT3 pathway, a regulator of EMT and aber-
rantly activated in CRC [9]. These studies prompted us
to ask whether GDH promotes CRC cell motility
through STAT3 mediated EMT Induction. Interesting,
we found that knockdown of GDH significant attenu-
ated STAT3 phosphorylation, and decreased Vimentin
and ZEB1 expression, while up-regulated E-cadherin expres-




Depth of invasion (T1-2/T3-4) 2.07 1.16
Tumor stage (I-II/III-IV) 2.01 1.11
Grade of differentiation (well, moderate/poor) 2.13 1.01
Lymph node metastasis (negative/positive) 4.68 2.45
Liver metastasis (negative/positive) 3.53 1.88
Venous invasion (negative/positive) 2.45 1.04
Nervous invasion (negative/positive) 2.25 1.25
GDH (low/high) 2.32 1.26
Disease-free survival
Lymph node metastasis (negative/positive) 5.73 2.68
Liver metastasis (negative/positive) 3.81 1.95
GDH (low/high) 2.48 1.25
HR relative risk, 95% CI 95% confidence interval.
*Statistically significant P<0.05, Cox proportional hazard regression model.pathway by AG490 significantly increased E-cadherin and
decreased ZEB1 and Vimentin expressions in CRC cells
(Figure 5A). Additionally, STAT3 pathway blockage could
significant inhibited cell proliferation (Figure 5B), and at-
tenuated the migration and invasion ability of CRC cells
(Figure 5C and D).
To further prove this hypothesis, we establish GDH-
overexpression SW480 cells, and found that GDH-
overexpression could promote STAT3 phosphorylation,
and up-regulate Vimentin and ZEB1 expression, while de-
crease E-cadherin expression (Additional file 2: Figure S2).
Furthermore, AG490 treatment could significantly increase
E-cadherin, and decrease ZEB1 and Vimentin expressions
in GDH-overexpression SW480 cells (Additional file 2:
Figure S2). Taken together, these results suggested that
GDH promotes CRC cell motility via STAT3 mediated
EMT induction.for overall and disease-free survival
Multivariate analysis
P-value HR 95% CI P-value
3.69 0.014* 1.82 0.98 3.38 0.060
3.63 0.021* 1.37 0.72 2.6 0.333
4.45 0.046* 1.28 0.53 3.05 0.581
8.94 <0.001* 3.47 1.66 7.27 0.001*
6.63 <0.001* 2.62 1.29 5.32 0.008*
5.8 0.042* 1.66 0.64 4.32 0.294
4.05 0.007* 1.14 0.59 2.19 0.703
4.26 0.007* 2.42 1.23 4.78 0.011*
12.28 <0.001* 4.70 2.08 10.59 <0.001*
7.46 <0.001* 2.38 1.16 4.87 0.018*
4.92 0.009* 2.17 1.05 4.47 0.037*
Figure 4 GDH knockdown impairs CRC cell proliferation and motility. Effects of GDH knockdown on cell proliferation (A), anchorage-independent
growth (B), migration (C) and invasion (D) of SW480 and LoVo cells. Data are presented as the mean ± SD based on three independent experiments.
*P < 0.05, **P < 0.01 compared to the control using Student’s t-test.
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Distant metastasis is a major cause of death in CRC
patients [23]. In this study, we found that GDH was
up-regulated in both CRC cells and clinical samples, and
correlated with poor survival and liver metastasis of
CRC. Importantly, our results revealed that GDH is an
independent prognostic factor for survival, which might
served as valuable prognosis markers for CRC. Finally,
we demonstrated that GDH promotes CRC cell motility
via STAT3 mediated EMT Induction. We show here for
the first time that GDH plays important roles in the
metastatic and aggressive biology of CRC, which mightserved as a predictive marker for CRC prognosis, and
presents a viable metabolic regulation strategy for CRC.
Metabolism is now recognized as a key feature of the
cancer cells, and increasingly evidence has linked cell
metabolism with cancer outcome [24-26]. Although in-
tensive studies have focused on the role of glutamine
metabolism in regulating growth and survival [27-29],
its role in motility and metastasis of cancers is not well
understood. Recently, Yang [9] revealed that high inva-
sive OVCA cells were strongly glutamine dependent,
and glutamine was a key mitochondrial substrate for
driving cancer metastasis by induction of STAT3 serine
Figure 5 GDH promotes CRC cell motility via STAT3 mediated EMT Induction. (A) Effects of GDH knockdown and AG490 on STAT3 Tyr705
phosphorylation, ZEB1 Vimentin and E-cadherin protein expression in CRC cells detected by western blot analysis. (B-D) Effects of GDH knockdown on
cell proliferation, migration and invasion of CRC cells. Data are presented as the mean ± SD based on three independent experiments. *P < 0.05,
**P < 0.01 compared to the control using Student’s t-test.
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ited melanoma cell migration via modulation of actin
cytoskeleton remodeling [30], and GDH activity was
required for glioblastoma cell to survive impairments of
glycolysis brought about by glucose deprivation [17]. In
the present study, we focus on the role of GDH, a key
enzyme converting glutamate to a-ketoglutarate then
entry into the TCA cycle. We found a high expression
of GDH in aggressive CRC cell lines, and altered GDH
expression affected cell proliferation, migration and
invasion. More importantly, we found direct clinical
evidence of a strong correlation between GDH over-
expression and unfavorable clinicopathologic vari-
ables such as tumor size, tumor stage, lymph node
metastasis and liver metastasis. These findings ro-
bustly suggested that GDH plays an important role in
CRC progression and metastasis.
It has been reported that approximately 30% of CRC
patients presenting with synchronous metastases and
70% ultimately developing liver metastases, and 50% of
CRC deaths are caused by liver metastases [31-33].
However, the mechanism of this aggressive biology ofCRC is largely unknown. Epithelial-mesenchymal tran-
sition (EMT) involves the loss of E-Cadherin mediated
cell adhesion and polarity, and is proposed to be a cru-
cial mechanism regulating the initial steps in metastatic
progression [34]. Several studies have examined the
possible role of EMT in CRC progression including liver
metastases [35-37]. To our knowledge, few studies have
described EMT with glutamine metabolism in CRC. In
this study, we found that loss function of GDH lead to
aberrant expression of EMT markers, and suppressed
cell proliferation and motility of CRC cells. Together
with previous studies, our findings further support the
crucial role of EMT in CRC metastasis.
Evidences showed that metabolism enzyme themselves
could be oncogenic by altering cell signaling that medi-
ated multiple aspects of cancer metastatic biology
[15,28,38]. Considering the crucial role of GDH involved
in CRC metastases, it is necessary to elucidate the
underlying mechanism of GDH mediated induction of
EMT. STAT3, a key regulator of EMT, has been reported
frequently activated in CRC [39-41]. Zhou [42] showed
that STAT3 could induce PTTG expression to facilitate
Liu et al. Journal of Translational Medicine  (2015) 13:144 Page 9 of 10tumor growth and metastasis of CRC. Xiong [43] found
that STAT3 down-regulated E-Cadherin expression via
ZEB1 in colorectal cancer cells. In this study, we dem-
onstrated that altered GDH expression significantly
affected the tyrosine phosphorylation of STAT3, and
GDH mediated invasiveness of CRC was STAT3
depended. Our results consist with previous findings
that tyrosine phosphorylation levels of STAT3 are
dependent on glutamine’s entry into the TCA cycle.
Conclusions
In conclusion, this study provided evidence supporting
the critical role of GDH in CRC progression and metas-
tasis. Our findings uncover a novel molecular mechan-
ism for CRC progression and metastasis and provide
novel metabolism therapeutic targets and strategies to
control CRC progression and metastasis.
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